BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 14534349)

  • 1. Residual disease in chronic myeloid leukemia after induction of molecular remission.
    Lange T; Niederwieser DW; Deininger MW
    N Engl J Med; 2003 Oct; 349(15):1483-4. PubMed ID: 14534349
    [No Abstract]   [Full Text] [Related]  

  • 2. Minimal residual disease in chronic myeloid leukemia.
    Löwenberg B
    N Engl J Med; 2003 Oct; 349(15):1399-401. PubMed ID: 14534331
    [No Abstract]   [Full Text] [Related]  

  • 3. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.
    Hughes TP; Kaeda J; Branford S; Rudzki Z; Hochhaus A; Hensley ML; Gathmann I; Bolton AE; van Hoomissen IC; Goldman JM; Radich JP;
    N Engl J Med; 2003 Oct; 349(15):1423-32. PubMed ID: 14534335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complete molecular remission in chronic myelogenous leukemia after imatinib therapy.
    Barbany G; Höglund M; Simonsson B;
    N Engl J Med; 2002 Aug; 347(7):539-40. PubMed ID: 12181416
    [No Abstract]   [Full Text] [Related]  

  • 5. Sustained clinical remission despite suboptimal molecular response to imatinib in e1a2 BCR-ABL chronic myeloid leukemia.
    Langabeer SE; Crampe M; Haslam K; Kelly J; Cahill MR
    Leuk Res; 2010 Jul; 34(7):e176-7. PubMed ID: 20153526
    [No Abstract]   [Full Text] [Related]  

  • 6. Complete response to imatinib mesylate treatment in a 12-month-old patient with chronic myeloid leukemia.
    Arancibia AM; Bendit I; Epelman S
    Pediatr Blood Cancer; 2008 May; 50(5):1078. PubMed ID: 18085674
    [No Abstract]   [Full Text] [Related]  

  • 7. BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria.
    Branford S; Seymour JF; Grigg A; Arthur C; Rudzki Z; Lynch K; Hughes T
    Clin Cancer Res; 2007 Dec; 13(23):7080-5. PubMed ID: 18056186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isolated central nervous system relapse after nine years of complete molecular remission in a lymphoid blast crisis of chronic myeloid leukemia treated with imatinib.
    Breccia M; Santopietro M; Cannella L; Federico V; Loglisci G; Serrao A; Petrucci L; Salaroli A; Nanni M; De Propris MS; Diverio D; Alimena G
    Leuk Res; 2011 Jun; 35(6):e91-2. PubMed ID: 21316103
    [No Abstract]   [Full Text] [Related]  

  • 9. Mobilization of Ph chromosome-negative peripheral blood stem cells in a child with chronic myeloid leukemia after imatinib-induced complete molecular remission.
    Woods-Swafford W; Vnencak-Jones CL; Loken MR; Manes B; Frangoul H
    Pediatr Blood Cancer; 2008 Mar; 50(3):639-41. PubMed ID: 16927371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response to imatinib in a patient with chronic myeloid leukemia simultaneously expressing p190(BCR-ABL) oncoprotein and JAK2V617F mutation.
    Caocci G; Atzeni S; Orrù N; Littera R; Culurgioni F; Marongiu F; La Nasa G
    Leuk Res; 2010 Jan; 34(1):e27-9. PubMed ID: 19748671
    [No Abstract]   [Full Text] [Related]  

  • 11. Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study.
    Hess G; Bunjes D; Siegert W; Schwerdtfeger R; Ledderose G; Wassmann B; Kobbe G; Bornhäuser M; Hochhaus A; Ullmann AJ; Kindler T; Haus U; Gschaidmeier H; Huber C; Fischer T
    J Clin Oncol; 2005 Oct; 23(30):7583-93. PubMed ID: 16234522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Monitoring of minimal residual disease in patients with chronic myeloleukemia: clinical value of real-time polymerase chain reaction].
    Chelysheva EIu; Turkina AG; Misiurin AV; Aksenova EV; Domracheva EV; Zakharova AV; Khoroshko ND
    Ter Arkh; 2007; 79(4):49-53. PubMed ID: 17564019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
    Cortes J; Talpaz M; O'Brien S; Jones D; Luthra R; Shan J; Giles F; Faderl S; Verstovsek S; Garcia-Manero G; Rios MB; Kantarjian H
    Clin Cancer Res; 2005 May; 11(9):3425-32. PubMed ID: 15867244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Detection and quantification of BCR-ABL transcripts in patients with chronic myeloid leukemia by real-time quantitative reverse transcriptase polymerase chain reaction].
    Xing W; Gu BW; Zhu YM; Jiang CL; Zhao RH; Wang AH; Sun HP; Li JM; Shen ZX; Chen Z; Chen SJ
    Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(7):453-7. PubMed ID: 15854550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imatinib failed to eradicate chronic myeloid leukemia in a patient with minimal residual disease.
    Franceschino A; Tornaghi L; Piazza R; Pogliani E; Gambacorti Passerini C
    Haematologica; 2006 Jun; 91(6 Suppl):ECR14. PubMed ID: 16785120
    [No Abstract]   [Full Text] [Related]  

  • 16. Complete cytogenetic and molecular response after imatinib treatment for chronic myeloid leukemia in a patient with atypical karyotype and BCR-ABL b2a3 transcript.
    Pienkowska-Grela B; Woroniecka R; Solarska I; Kos K; Pastwińska A; Konopka L; Majewski M
    Cancer Genet Cytogenet; 2007 Apr; 174(2):111-5. PubMed ID: 17452251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation.
    Merante S; Orlandi E; Bernasconi P; Calatroni S; Boni M; Lazzarino M
    Haematologica; 2005 Jul; 90(7):979-81. PubMed ID: 15996937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic myeloid leukemia with an e13a3 BCR-ABL fusion: benign course responsive to imatinib with an RT-PCR advisory.
    Snyder DS; McMahon R; Cohen SR; Slovak ML
    Am J Hematol; 2004 Feb; 75(2):92-5. PubMed ID: 14755375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Targeted therapy with imatinib has reformed the treatment of chronic myeloid leukemia].
    Nielsen JL
    Ugeskr Laeger; 2003 May; 165(20):2111. PubMed ID: 12812107
    [No Abstract]   [Full Text] [Related]  

  • 20. Induction chemotherapy and post-remission imatinib therapy for de Novo BCR-ABL-positive AML.
    Lazarevic V; Golovleva I; Nygren I; Wahlin A
    Am J Hematol; 2006 Jun; 81(6):470-1. PubMed ID: 16680752
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.